INFORMATION for the USER ZOPICLONE 3.75 Mg FILM

Total Page:16

File Type:pdf, Size:1020Kb

INFORMATION for the USER ZOPICLONE 3.75 Mg FILM MRP NL/H/269-01 05 July 2010 PACKAGE LEAFLET: INFORMATION FOR THE USER ZOPICLONE 3.75 mg FILM-COATED TABLETS Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Zopiclone is and what it is used for 2. What you need to know before you take Zopiclone 3. How to take Zopiclone 4. Possible side effects 5. How to store Zopiclone 6. Contents of the pack and other information 1. WHAT ZOPICLONE IS AND WHAT IT IS USED FOR Zopiclone belongs to a group of medicines called hypnotics. These are medicines which help you sleep. Zopiclone is used for the short-term treatment of severe sleeping difficulties, which are causing you extreme distress. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZOPICLONE DO NOT take Zopiclone: if you are allergic (hypersensitive) to zopiclone or any of the other ingredients of this medicine (listed in section 6) if you are allergic to any other sleeping tablets or tablets taken for anxiety if you have myasthenia gravis (a muscle disease where the muscles become weak and tire easily) if you have severe breathing difficulties, including difficulty in breathing or stopping of breathing for very short periods when asleep (sleep apnoea) if you have severe liver problems. In patients with severe liver problems encephalopathy (a brain disorder) may develop if you are under the age of 18 Warnings and precautions Talk to your doctor or pharmacist before taking Zopiclone Before treatment with Zopiclone Common-pl-zopiclone3_75mgjuly2010tracked 1 REG0047870 Version 0.10 Approved Page 1 of 10 MRP NL/H/269-01 05 July 2010 the cause of the sleep disturbances should be clarified underlying diseases should be treated. General information about effects observed after use of benzodiazepines and benzodiazepine-like agents (such as Zopiclone) or other hypnotics which the prescribing doctor should consider is described in the following: When taking this medicine there is a risk of dependence (a need to keep taking the medicine). This may be physical dependence, where the body becomes used to the presence of the medicine and stopping treatment causes withdrawal symptoms and/or mental dependence, where you develop a craving for the medicine. The risk is greater if you have ever had a history of alcohol or drug abuse, or suffer from a personality disorder. When stopping this medicine you may experience withdrawal effects (rebound insomnia) (see section 3, If you stop taking Zopiclone). Withdrawal effects may also occur between doses, especially if you are taking a high dose of Zopiclone. It may be accompanied by other reactions: mood changes, sleep disturbances, anxiety and restlessness. It is important that you are aware of the possibility of such symptoms in order to minimize your anxiety. Behavioural effects may occur while taking Zopiclone. During the use of benzodiazepines and benzodiazepine-like substances, the following psychiatric and paradoxical reactions may occur: restlessness, agitation, irritability, aggression, having false beliefs that persist even with having evidence that the belief is not true (delusions), outbursts of rage, nightmares, seeing, hearing or feeling things that are not real (hallucinations), severe mental disorders characterized by disturbance of personality and loss of contact with reality (psychoses), unsuitable behaviour, other behavioural disturbances. The risk of these reactions is higher in elderly patients. If you feel any of the symptoms listed above, you should stop taking Zopiclone. Ask your doctor for advice. Sleep walking (somnambulism) and other associated behaviours such as “sleep driving”, preparing and eating food, or making phone calls, with memory loss (amnesia) for the event, have been reported in patients who have taken zopiclone and were not fully awake. The risk of such behaviours is increased if alcohol or certain other medicines (such as narcotic analgesics, antipsychotic agents, hypnotics or anxiolytics/sedatives) are used during treatment with zopiclone if zopiclone is used at doses exceeding the maximum recommended dose If you develop such behaviours, please inform your doctor immediately. Your doctor may discontinue the treatment with zopiclone. After stopping the treatment with a benzodiazepine or a benzodiazepine-like substance, a temporary syndrome called rebound insomnia may occur. Sleeplessness (insomnia) may return in a more severe form. Other symptoms may be mood changes, anxiety and restlessness. The risk of withdrawal or rebound symptoms is higher if you stop the treatment suddenly. Therefore, your doctor will advise you to reduce your dose of zopiclone gradually. Common-pl-zopiclone3_75mgjuly2010tracked 2 REG0047870 Version 0.10 Approved Page 2 of 10 MRP NL/H/269-01 05 July 2010 The effect of some benzodiazepines or benzodiazepine-like substances may decrease after repeated use for a few weeks. This process is called tolerance. Please ask your doctor, if you have the feeling that the effect of zopiclone decreases after repeat use for a few weeks. Benzodiazepines and benzodiazepine-like substances may cause a short-term memory loss (anterograde amnesia). This occurs particularly a few hours after taking the medicine. In order to reduce this risk, make sure you will be able to have an uninterrupted sleep of 7-8 hours. Special patient groups Benzodiazepines and benzodiazepine-like agents (such as Zopiclone) should be administered with care in - Older people and debilitated patients They should receive a lower dose (see 3. “How to use Zopiclone”). Zopiclone has a muscle- relaxant effect. For this reason, especially elderly patients are at risk of falling and consequently of hip joint fractures when getting out of bed at night. - Patients with chronic dyspnoea It is proven that benzodiazepines can impair breathing. It should be considered as well that anxiety or inner restlessness has been described as signs of dyspnoea. - Patients with alcohol and drug abuse in their medical history Extreme caution is required. These patients should carefully be supervised during treatment with Zopiclone, as they are at risk of habituation and psychological dependence. Talk to your doctor before taking Zopiclone if you: are elderly or frail. Due to the muscle relaxing effect of Zopiclone, there is a danger of falls, particularly for the elderly when getting up at night have a history of alcohol or drug abuse have psychiatric problems or mental illness (including personality disorders), depression or anxiety (as thoughts of suicide may occur) have breathing difficulties have mild or moderate liver problems You are at risk of brain damage (encephalopathy) have kidney problems. If you are elderly, you are more likely to experience certain of the side effects. Other medicines and Zopiclone Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Talk to your doctor if you are taking any of the following: muscle relaxants e.g. baclofen, as their muscle relaxing effect may be increased medicines which may increase the effect of Zopiclone, such as: other hypnotics e.g. nitrazepam, used as short-term treatments to help you to sleep anxiolytics or sedatives e.g. diazepam, used to alleviate anxiety antidepressants e.g. amitriptyline, fluoxetine, and those known as monoamine oxidase inhibitors (MAOIs) e.g. phenelzine Common-pl-zopiclone3_75mgjuly2010tracked 3 REG0047870 Version 0.10 Approved Page 3 of 10 MRP NL/H/269-01 05 July 2010 antipsychotic drugs also known as neuroleptics or tranquillisers e.g. chlorpromazine, used to treat mental illness strong (narcotic) painkillers e.g. codeine, morphine drugs to treat epilepsy e.g. carbamazepine, phenytoin anaesthetics sedative antihistamines e.g. alimemazine, chlorphenamine, used to treat allergies and allergic reactions and which also cause drowsiness Medicines which may reduce the effect of Zopiclone, such as: erythromycin (an antibiotic) antibiotics of the macrolide class (used to treat bacterial infections), e.g. erythromycin antimycotics of the azole group (used to treat fungal infections) HIV protease inhibitors (used to treat AIDS). Medicines which may reduce the effect of Zopiclone, such as: phenobarbital and phenytoin (used to treat seizures) carbamazepine (used to treat seizures and mood disorders) rifampicin (antibiotic) products containing St. John's wort (herb used to treat depression and anxiety). Tell the hospital or dentist you are taking Zopiclone if you are to have an operation or treatment requiring an anaesthetic. Zopiclone with food, drink and alcohol DO NOT drink alcohol whilst taking these tablets as the sedative effect of Zopiclone may be increased. You should not take the tablets with grapefruit juice, as this will change and intensify the effect of Zopiclone in an unforeseeable way. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Zopiclone is not recommended if you are pregnant or planning to become pregnant. It should not be taken during pregnancy, especially not in the first trimester because no sufficient data is available to evaluate safe administration of Zopiclone during pregnancy and the lactation period. Although Zopiclone did not show any malformations or any effect damaging the embryo in animal studies, the safety during human pregnancy has not been verified. If your doctor has decided that you should take Zopiclone during the last three months of pregnancy or during labour, your baby may have a low body temperature, breathing problems, decreased muscle tone, and suckling reflex (“floppy infant syndrome”).
Recommended publications
  • Comparison of Short-And Long-Acting Benzodiazepine-Receptor Agonists
    J Pharmacol Sci 107, 277 – 284 (2008)3 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Comparison of Short- and Long-Acting Benzodiazepine-Receptor Agonists With Different Receptor Selectivity on Motor Coordination and Muscle Relaxation Following Thiopental-Induced Anesthesia in Mice Mamoru Tanaka1, Katsuya Suemaru1,2,*, Shinichi Watanabe1, Ranji Cui2, Bingjin Li2, and Hiroaki Araki1,2 1Division of Pharmacy, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan 2Department of Clinical Pharmacology and Pharmacy, Neuroscience, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan Received November 7, 2007; Accepted May 15, 2008 Abstract. In this study, we compared the effects of Type I benzodiazepine receptor–selective agonists (zolpidem, quazepam) and Type I/II non-selective agonists (zopiclone, triazolam, nitrazepam) with either an ultra-short action (zolpidem, zopiclone, triazolam) or long action (quazepam, nitrazepam) on motor coordination (rota-rod test) and muscle relaxation (traction test) following the recovery from thiopental-induced anesthesia (20 mg/kg) in ddY mice. Zolpidem (3 mg/kg), zopiclone (6 mg/kg), and triazolam (0.3 mg/kg) similarly caused an approximately 2-fold prolongation of the thiopental-induced anesthesia. Nitrazepam (1 mg/kg) and quazepam (3 mg/kg) showed a 6- or 10-fold prolongation of the anesthesia, respectively. Zolpidem and zopiclone had no effect on the rota-rod and traction test. Moreover, zolpidem did not affect motor coordination and caused no muscle relaxation following the recovery from the thiopental-induced anesthesia. However, zopiclone significantly impaired the motor coordination at the beginning of the recovery. Triazolam significantly impaired the motor coordination and muscle relaxant activity by itself, and these impairments were markedly exacerbated after the recovery from anesthesia.
    [Show full text]
  • Herbal Remedies and Their Possible Effect on the Gabaergic System and Sleep
    nutrients Review Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep Oliviero Bruni 1,* , Luigi Ferini-Strambi 2,3, Elena Giacomoni 4 and Paolo Pellegrino 4 1 Department of Developmental and Social Psychology, Sapienza University, 00185 Rome, Italy 2 Department of Neurology, Ospedale San Raffaele Turro, 20127 Milan, Italy; [email protected] 3 Sleep Disorders Center, Vita-Salute San Raffaele University, 20132 Milan, Italy 4 Department of Medical Affairs, Sanofi Consumer HealthCare, 20158 Milan, Italy; Elena.Giacomoni@sanofi.com (E.G.); Paolo.Pellegrino@sanofi.com (P.P.) * Correspondence: [email protected]; Tel.: +39-33-5607-8964; Fax: +39-06-3377-5941 Abstract: Sleep is an essential component of physical and emotional well-being, and lack, or dis- ruption, of sleep due to insomnia is a highly prevalent problem. The interest in complementary and alternative medicines for treating or preventing insomnia has increased recently. Centuries-old herbal treatments, popular for their safety and effectiveness, include valerian, passionflower, lemon balm, lavender, and Californian poppy. These herbal medicines have been shown to reduce sleep latency and increase subjective and objective measures of sleep quality. Research into their molecular components revealed that their sedative and sleep-promoting properties rely on interactions with various neurotransmitter systems in the brain. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a major role in controlling different vigilance states. GABA receptors are the targets of many pharmacological treatments for insomnia, such as benzodiazepines. Here, we perform a systematic analysis of studies assessing the mechanisms of action of various herbal medicines on different subtypes of GABA receptors in the context of sleep control.
    [Show full text]
  • Zopiclone 7.5Mg Tablets PIL V5P1
    PATIENT INFORMATION LEAFLET Patients with liver or kidney problems Very Rare (may affect up to 1 in 10,000 The usual starting dose is 3.75mg (½ a tablet). people) ZOPICLONE 7.5mg TABLETS • Change in blood tests (increase of liver Patients with Respiratory Insufficiency enzymes in the blood) Read this leaflet carefully BEFORE you start taking Zopiclone Tablets because it A reduced dosage is recommended (frequency cannot be estimated contains important information for you. Not known Pharmacode location from the available data) • Keep this leaflet. You may need to read it again. Use in Children and adolescents • Restlessness • If you have further questions, please ask your doctor or your pharmacist. Zopiclone Tablets are NOT recommended for • Delusion • This medicine has been prescribed for you only. Do not pass it on to others. It may harm children. • Anger them, even if their signs of illness are the same as yours. • Muscular weakness • If you get any of the side effects talk to your doctor or pharmacist. This includes any Your treatment will usually be for less than 4 • Loss of co-ordination possible side effects not listed in this leaflet. See section 4 weeks, and the doctor may reduce your dose near the end of your course. If you take • Loss of memory WHAT IS IN THIS LEAFLET Zopiclone longer than this, the medicine may • Double vision 1. What Zopiclone Tablets are and what they are used for not work as well, you may become dependent • Unusual skin sensations such as numbness, 2. What you need to know before you take Zopiclone Tablets and you may have withdrawal symptoms when burning, tingling or prickling (paraesthesia) 3.
    [Show full text]
  • Zopiclone (Imovane) COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: Jan 7, 2017
    Zopiclone (Imovane) COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: Jan 7, 2017 Medication: Zopiclone 5 mg or 7.5 mg What is Zopiclone? Zopiclone tablets are sleeping pills (hypnotics) which work by acting on the brain to cause sleepiness. They may be used for the treatment of difficulties in falling asleep. The medication effects typically only last about 3 hours so it may not be helpful in keeping you asleep Expected Benefit: A benefit can be noticed on the first night In some patients it loses its efficacy after a while, and may need to be switched to another drug Watch for possible side effects: This list of side effects is important for you to be aware of; however, it is also important to remember that not all side effects happen to all people. Many of these less serious side effects will improve over the first few days of taking the medications. If you have problems with these side effects talk with your doctor or pharmacist: Metallic taste Dizziness Off balance Blurred vision Dry mouth Rarely, some individuals will still feel drowsy the next morning Rarely, some individuals will feel agitated instead of drowsy Stopping the medication: When you stop taking zopiclone, your doctor may advise you to reduce the dose slowly to help prevent your sleep problems from returning. How to use and store this medication: Take this medication with or without food Dosing Schedule: Take just before bedtime because it has a quick onset of action Start with ½ tablet at bedtime (i.e., 2.5 mg or 3.75 mg depending on whether you are prescribed a 5 mg or 7.5 mg tablet) Increase the dose by ½ a tablet every night or two until you can fall asleep within 20 – 30 minutes The usual dose range o 2.5 mg – 7.5 mg for the 5 mg tablets, or o 3.75 mg – 7.5 mg for the 7.5 mg tablets Page 1 Zopiclone (Imovane) COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: Jan 7, 2017 Drugs and Foods to Avoid: Ask your doctor or pharmacist before using any other medication, including non- prescription medication (over-the-counter medication) and herbal products.
    [Show full text]
  • Zopiclone Produces Effects on Human Performance Similar to Flurazepam, Lormetazepam and Triazolam
    Br. J. clin. Pharmac. (1986), 21, 647-653 Zopiclone produces effects on human performance similar to flurazepam, lormetazepam and triazolam A. N. GRIFFITHS', D. M. JONES2 & A. RICHENS1 'Department of Pharmacology and Therapeutics, University of Wales College of Medicine, Cardiff and 2Department of Applied Psychology, University of Wales Institute of Science and Technology, Cardiff 1 The cognitive function and psychomotor performance of 10 healthy male volunteers were measured following single oral doses of: zopiclone (7.5 mg), flurazepam (15 mg), lormetazepam (1 mg), triazolam (0.25 mg) and placebo. 2 The performance tests selected (stroop task, five choice serial reaction time, memory span, logical reasoning, mood and saccadic eye movement analysis) were thought to reflect aspects of normal daily activity. 3 The tests demonstrated a clear reduction of performance for all active treatments. No drug emerged as the most potent sedative overall, as each of the tests was affected to a different degree by each drug. 4 Drug effects were not qualitatively different between active treatments so that zopi- clone was indistinguishable from the three benzodiazepines with which it was compared. Keywords zopiclone benzodiazepines human performance saccadic eye movements Introduction Zopiclone is a cyclopyrrolone derivative which, (7.5 mg) has been shown to be effective as an although structurally unrelated to the benzodia- hypnotic (Wickstrom & Giercksky, 1980), zepines, shares their pharmacological profile. and furthermore, Lader & Denney (1983) Binding studies have shown that zopiclone binds reported this dose to be the preferred hypnotic to brain benzodiazepine receptors but is not dose. recognised by peripheral (renal) benzodiazepine The marketed benzodiazepines selected for receptors.
    [Show full text]
  • Medications and Electroconvulsive Therapy
    Graylands Hospital Drug Bulletin Medications and Electroconvulsive Therapy North Metropolitan Health Service - Mental Health June 201 8 Vol 2 5 No. 1 ISSN 1323 -1251 A review by Sienaert et al concluded that ECT Introduction can be administered safely with Electroconvulsive therapy (ECT) has been anticonvulsants with no reduction in efficacy.6 shown to be highly effective and safe for A trial comparing the efficacy of ECT with or many psychiatric disorders such as major without concurrent sodium valproate therapy depressive disorder, catatonia, psychosis and concluded that continuation of valproate mania.1 It is well documented that certain during ECT does not impair or enhance the medications interact with ECT and can impact efficacy of ECT.7 Similarly, a small clinical trial on the quality of the treatment or cause of 19 patients concluded that therapeutic adverse effects. This bulletin attempts to doses of lamotrigine does not significantly summarise the effect of medications on ECT influence the stimulus dose required or length and vice versa. of ECT-induced seizures.8 Benzodiazepines Medication Optimisation Pre-ECT Benzodiazepines are gamma-aminobutyric Anticonvulsants acid (GABA) receptor modulators which Anticonvulsants, in theory, will reduce the increase seizure threshold, shorten seizure quality of seizures obtained with ECT as they duration and reduce seizure intensity.2 are designed to prevent seizures. However, evidence of anticonvulsants interfering with Multiple studies have shown that the efficacy of ECT is lacking.2 Most guidelines benzodiazepines affect the efficacy of right still advise cessation of anticonvulsants prior unilateral (RUL) ECT but not BT ECT. 2, 4, 9, 10 It to ECT.
    [Show full text]
  • Drug-Facilitated Sexual Assault in the U.S
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Estimate of the Incidence of Drug-Facilitated Sexual Assault in the U.S. Document No.: 212000 Date Received: November 2005 Award Number: 2000-RB-CX-K003 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. AWARD NUMBER 2000-RB-CX-K003 ESTIMATE OF THE INCIDENCE OF DRUG-FACILITATED SEXUAL ASSAULT IN THE U.S. FINAL REPORT Report prepared by: Adam Negrusz, Ph.D. Matthew Juhascik, Ph.D. R.E. Gaensslen, Ph.D. Draft report: March 23, 2005 Final report: June 2, 2005 Forensic Sciences Department of Biopharmaceutical Sciences (M/C 865) College of Pharmacy University of Illinois at Chicago 833 South Wood Street Chicago, IL 60612 ABSTRACT The term drug-facilitated sexual assault (DFSA) has been recently coined to describe victims who were given a drug by an assailant and subsequently sexually assaulted. Previous studies that have attempted to determine the prevalence of drugs in sexual assault complainants have had serious biases. This research was designed to better estimate the rate of DFSA and to examine the social aspects surrounding it. Four clinics were provided with sexual assault kits and asked to enroll sexual assault complainants.
    [Show full text]
  • Standard of Practice Prescribing Benzodiazepines & Z-Drugs
    Standard of Practice Prescribing Benzodiazepines & Z-Drugs (including Zopiclone & other drugs) Initial Approval: September 25, 2020 Effective Date: November 1, 2020 Standards of Practice of Medicine set out the requirements related to specific aspects for the quality of the practice of medicine. Standards of Practice of Medicine provide more detailed information than contained in the Regulated Health Professions Act, Regulations, and Bylaws. All members must comply with Standards of Practice of Medicine, per section 86 of the Regulated Health Professions Act. This Standard of Practice of Medicine is made under the authority of section 82 of the Regulated Health Professions Act and section 15 of the CPSM Standards of Practice Regulation. PREAMBLE This Standard establishes the standard of practice and ethical requirements of all members in relation to prescribing benzodiazepines and/or Z-Drugs for maximum safety for all patients whether in the community or in a health care facility. This Standard does not apply to the use of these drugs in the treatment of cancer, palliative and end-of-life patients, seizure disorders, bipolar/psychotic disorder, and acute alcohol withdrawal*. Medical evidence of the risk to benefit ratio of prescribing benzodiazepines and/or Z-Drugs is altered over time, so prescribing these drugs must be in accordance with current medical knowledge. This Standard recognizes that in prescribing benzodiazepines and/or Z-Drugs each member exercises their clinical judgment, which is to be that of a member acting reasonably in the circumstances with current medical knowledge. *If prescribing for any of these conditions please include the medical condition on the prescription for the awareness of the pharmacist for dispensing purposes.
    [Show full text]
  • Eszopiclone-Lunesta-Monograph.Pdf
    Eszopiclone (Lunesta) Classification: Hypnotic Pharmacology The mechanism of action of eszopiclone (Lunesta) as a hypnotic is unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors. Indication -FDA & literature supported non-FDA Treatment of insomnia (decreased sleep latency and improved sleep maintenance) Pharmacokinetics Pharmacokinetic Parameter Details Absorption Rapidly absorbed. Peak plasma concentrations achieved within approximately 1 hour after oral administration Distribution Weakly bound to plasma protein (52-59%) Metabolism Hepatic via oxidation and demethylation (CYP2E1, 3A4); (S)- N-desmethyl zopiclone metabolite has less activity than parent compound Excretion Urine (up to 75%, primarily as metabolites; < 10% as parent drug) 1 Texas Health and Human Services ● hhs.texas.gov T-max Oral Elimination Dose Z-drug (h) bioavailability t ½ (h) range Metabolism Zolpidem 1-2 65-70% 2.5-3 5-10 mg CYP 3A4, IR 2C9, 1A2 Zolpidem 1.5-2.5 65-70% 2.5-3 6.25-12.5 ER mg Zopiclone 1.5-2 75-80% 5-6 3.75-7.5 CYP 3A4, 2C8 Eszopiclone 1-1.5 75-80% 6-7 1-3 mg CYP 3A4, 2E1 Zaleplon 0.7-1.4 30% 1 5-20 mg Aldehyde oxidase, CYP 3A4 Dosage/Administration The recommended starting dose in adults is 1 mg, once daily immediately before bedtime. Dosing can be raised to 2 mg or 3 mg if clinically indicated. The total dose should not exceed 2 mg in elderly or debilitated patients. No dose adjustment is necessary for patients with mild-to-moderate hepatic impairment.
    [Show full text]
  • Zopiclone/Eszopiclone Elisa Kit Instructions Product #133819 & 133815 (Rtu) Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology ZOPICLONE/ESZOPICLONE ELISA KIT INSTRUCTIONS PRODUCT #133819 & 133815 (RTU) FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Zopiclone/Eszopiclone and/or other metabolites in human urine and blood. DESCRIPTION Neogen Corporation’s Zopiclone/Eszopiclone ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of an acid stop.
    [Show full text]
  • The Pharmacology of Midazolam and Thiopental with Regard to the Lethal Injection Protocol in the State of Mississippi
    Litigation Report – Expert Opinion THE PHARMACOLOGY OF MIDAZOLAM AND THIOPENTAL WITH REGARD TO THE LETHAL INJECTION PROTOCOL IN THE STATE OF MISSISSIPPI Re: Mississippi Lethal Injection Case January 15, 2016 Researched and written by: Craig W. Stevens, Ph.D. Professor of Pharmacology Oklahoma State University-Center for Health Sciences 1111 W. 17th Street Tulsa, OK 74107 Prepared for and submitted to: Emily Washington Attorney Roderick & Solange MacArthur Justice Center 4400 S. Carrollton Ave. New Orleans, LA 70119 Expert Report: MISS lethal injection Sections ______________________________________________________________________________ 1. Background and Qualifications of the Author ................................................................... 3 2. Midazolam and Thiopental are not Pharmacologically Equivalent .................................... 3 A. Pharmacological Equivalency and Pharmacological Substitution ....................................... 3 B. Pharmacological Classification of Midazolam and Thiopental ............................................ 4 C. Mechanism of Action of Midazolam and Thiopental ........................................................... 5 D. The Pharmacology of the Partial Agonist, Midazolam, and Full Agonist, Thiopental ......... 6 E. Therapeutic Uses of Benzodiazepines and Barbiturates ...................................................... 8 F. DEA Scheduling of Midazolam and Thiopental..................................................................... 9 G. Summary .............................................................................................................................
    [Show full text]
  • Medications for Insomnia: Drug Information to Support Drug Therapy Decisions B.C
    Medications for Insomnia: Drug Information to Support Drug Therapy Decisions B.C. Provincial Academic Detailing (PAD) Service December 2020 Learning Objectives: Participants in this PAD session will have the opportunity to discuss: . The strength of recommendations for and against specific medications for insomnia in contemporary clinical practice guidelines . Prescribing principles applicable to medications for insomnia . Drug information relevant to the prescribing, deprescribing and monitoring of medications for insomnia with a focus on the most commonly prescribed medications BC’s Provincial Academic Detailing (PAD) Service is offered free of charge to health care professionals. The service is provided by health authorities and supported by the Ministry of Health. Relevant topics are identified in consultation with various groups. All written materials are externally reviewed by clinicians and experts in critical appraisal. Medications for Insomnia: Evidence to Practice Apply prescribing principles Clinical practice guidelines that include: Many people in British Columbia make weak recommendations are prescribed higher than the for and against specific . discussion of goals of therapy recommended doses of BZRAs, medications, reflecting . medication review such as zopiclone. To reduce uncertainty in the evidence for . attention to dose & drug the risk of next day impairment, medication benefits interactions Health Canada has lowered versus harms. communication of risk starting and maximum doses. review of ongoing use BZRAs: benzodiazepine receptor agonists (zopiclone, eszopiclone, zolpidem) Medications for Insomnia: Prescribing Principles Use low starting doses Decisions about Ask patients Review for medications and note changes to the effectiveness can be “What do you hope that can cause Implement maximum doses of made early. The drug to achieve with insomnia & consider non-pharmacologic benzodiazepine receptor approval process insomnia the potential for strategies.1-3 agonists (intended to requires evidence of treatment?”1 prescribing cascades.
    [Show full text]